The aim of the study was to evaluate whether the insertion/deletion polymorphism (rs3783553) locating in the 3' untranslated region (3'UTRs) of IL-1A was related to the risk of gastric cancer(GC) in a Chinese population and explore the possible molecular mechanism.
METHODS:
Genomic DNA was extracted from peripheral venous blood of 519 GC patients and 536 healthy control individuals. The IL-1A rs3783553 polymorphism was genotyped by using a polymerase chain reaction assay. The vectors containing the insertion or deletion allele were constructed, and luciferase assay was used to detect the effect of the polymorphism on the transcriptional activity of IL-1A.
RESULTS:
Strong evidence of association was observed between theIL-1A rs3783553 polymorphism and susceptibility to GC in the study. In addition, the `TTCA' insertion allele of rs3783553 disrupts the binding site for miR-122 and miR-378, thereby increasing transcription of IL-1α in vitro.
CONCLUSION:
These findings suggest that functional polymorphism rs3783553 in IL-1A could contribute to GC susceptibility, possibly or at least partially through affecting the transcriptional activity of IL-1A.
KrejsG.J.Gastric Cancer: Epidemiology and Risk Factors. Digest Dis.2010; 28(4-5): 600-3.
2.
JemalA., BrayF., CenterM.M. et al. Global Cancer Statistics. Ca-Cancer J Clin.2011; 61(2): 69-90.
3.
GuggenheimD.E., ShahM.A.Gastric cancer epidemiology and risk factors. J Surg Oncol.2013; 107(3): 230-6.
4.
YoshidaT., OnoH., KuchibaA., SaekiN., SakamotoH.Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: Gastric cancer as an example. Cancer Sci.2010; 101(7): 1582-9.
5.
ShiY.Y., HuZ.B., WuC. et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet.2011; 43(12): 1215-U66.
6.
BartelD.P.MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell.2004; 116(2): 281-97.
YuZ.B., LiZ., JolicoeurN. et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic acids research.2007; 35(13): 4535-41.
9.
SethupathyP., BorelC., GagnebinM. et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. American journal of human genetics.2007; 81(2): 405-13.
10.
MishraP.J., HumeniukR., MishraP.J. et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proceedings of the National Academy of Sciences of the United States of America.2007; 104(33): 13513-8.
11.
GaoY., HeY., DingJ. et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis.2009; 30(12): 2064-9.
12.
ChinL.J., RatnerE., LengS.G. et al. A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk. Cancer research.2008; 68(20): 8535-40.
13.
MaJ., SawaiH., MatsuoY. et al. Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. The Journal of surgical research.2008; 148(2): 197-204.
14.
SakamotoK., HikibaY., NakagawaH. et al. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology.2010; 139(1): 226-38e6.
15.
YangZ.H., DaiQ., ZhongL. et al. Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Molecular carcinogenesis.2011; 50(3): 208-14.
16.
ZengX.F., LiJ. and LiS.B.A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2014; 35(1): 265-268.
17.
ZhangY., SturgisE.M., SunY. et al. A functional variant at miRNA-122 binding site in IL-1 alpha 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer. European journal of cancer 2015; 51(11): 1415-1423.
18.
TanimotoK., YoshigaK., EguchiH. et al. Hypoxia-in-ducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis.2003; 24(11): 1779-83.
19.
AllenR.C., GravesG., BudowleB.Polymerase Chain-Reaction Amplification Products Separated on Rehydratable Polyacrylamide Gels and Stained with Silver. Biotechniques.1989; 7(7): 736-44.
20.
TomimatsuS., IchikuraT., MochizukiH.Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer.2001; 91(7): 1272-6.
21.
ItoR., KitadaiY., KyoE. et al. Interleukin-1-Alpha Acts as an Autocrine Growth Stimulator for Human Gastric-Carcinoma Cells. Cancer research.1993; 53(17): 4102-6.
22.
MccuneC.S., MarquisD.M.Interleukin-1 as an Adjuvant for Active Specific Immunotherapy in a Murine Tumor-Model. Cancer research.1990; 50(4): 1212-5.
23.
HaradaT., KanN., OkinoT. et al. The Induction of Specific Antitumor Immunity by in-Vivo Treatment with Interleukin-1 and Sonicated Tumor Extract in a Murine Model. Surgery Today-the Japanese Journal of Surgery.1994; 24(6): 561-3.
24.
SondakV.K., TuckM.K., ShuS., YoshizawaH., ChangA.E.Enhancing Effect of Interleukin 1-Alpha Administration on Antitumor Effector T-Cell Development. Arch Surg-Chicago.1991; 126(12): 1503-9.
25.
HornungR.L., KiertscherS.M., MathewsH.L.Systemic IL-1 and adjuvant treatment of an experimental tumor. I. Immune status following tumor rechallenge. Biotherapy.1992; 5(3): 227-37.
26.
StidhamK.R., RicciW.M., VervaertC. et al. Modulation of specific active immunization against murine melanoma using recombinant cytokines. Surg Oncol.1996; 5(5-6): 221-9.
27.
KiertscherS.M., MathewsH.L.Systemic IL-1 and adjuvant treatment of an experimental tumor. II. Immune status during primary tumor challenge. Biotherapy.1992; 5(4): 259-74.
28.
ShenR.N., WuB., LuL., KaiserH.E., BroxmeyerH.E.Recombinant human interleukin-1 alpha: A potent bio-immunomodifier in vivo in immunosuppressed mice induced by cyclophosphamide, retroviral infection and surgical stress. In vivo.1994; 8(1): 59-63.
29.
BelardelliF., CiolliV., TestaU. et al. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer.1989; 44(6): 1108-16.
30.
ChangM.J., YuW.D., ReynoL.M. et al. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer research.1994; 54(20): 5380-6.
31.
Lagos-QuintanaM., RauhutR., YalcinA. et al. Identification of tissue-specific microRNAs from mouse. Current biology: CB.2002; 12(9): 735-9.
32.
GirardM., JacqueminE., MunnichA., LyonnetS., Henrion-CaudeA.miR-122, a paradigm for the role of microRNAs in the liver. Journal of hepatology.2008; 48(4): 648-56.
33.
WuX., SomloG., YuY. et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. Journal of translational medicine.2012; 10(42).
34.
IinoI., KikuchiH., MiyazakiS. et al. Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis. Cancer Sci.2013; 104(5): 624-30.
35.
ChenQ.J., GeX.J., ZhangY.C. et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncology reports.2014; 31(4): 1863-70.
36.
TsaiW.C., HsuP.W.C., LaiT.C. et al. MicroRNA-122, a Tumor Suppressor MicroRNA that Regulates Intrahepatic Metastasis of Hepatocellular Carcinoma. Hepatology.2009; 49(5): 1571-82.
37.
HsuS.H., WangB., KotaJ. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. Journal of Clinical Investigation.2012; 122(8): 2871-83.
38.
UefujiK., IchikuraT., Mochizuki, H. Increased expression of interleukin-1alpha and cyclooxygenase-2 in human gastric cancer: A possible role in tumor progression. Anticancer research.2005; 25(5): 3225-30.
39.
KemikO., SumerA., KemikA.S. et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol.2010; 8.
40.
FuruyaY., IchikuraT., MochizukiH.Interleukin-1 alpha concentration in tumors as a risk factor for liver metastasis in gastric cancer. Surgery Today-the Japanese Journal of Surgery.1999; 29(3): 288-9.
41.
GuoJ.M., MiaoY., XiaoB.X. et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroen Hepatol.2009; 24(4): 652-7.
42.
FeiB.J., WuH.R.MiR-378 Inhibits Progression of Human Gastric Cancer MGC-803 Cells by Targeting MAPK1 In Vitro. Oncol Res.2012; 20(12): 557-64.
43.
LiuH.S., ZhuL., LiuB.Y. et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer letters.2012; 316(2): 196-203.
44.
DengH.X., GuoY.N., SongH.J. et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene.2013; 518(2): 351-9.
